![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Pharmacokinetics of Cyclosporine and Tacrolimus, Following Coadministration with the Direct Acting Antiviral Combination, ABT-450/r,
Ombitasvir and Dasabuvir, in Liver Transplant Patients with Genotype-1 HCV Infection
|
|
|
Reported by Jules Levin
AASLD 2014 Nov 7-11 Boston
Prajakta Badri, Apurvasena Parikh, Eoin Coakley, Bifeng Ding, Walid Awni, Sandeep Dutta, Rajeev Menon
AbbVie Inc., North Chica
AASLD: HIGH SUSTAINED VIROLOGIC RESPONSE RATES IN LIVER TRANSPLANT RECIPIENTS WITH RECURRENT HCV GENOTYPE 1 INFECTION RECEIVING ABT-450/r/OMBITASVIR + DASABUVIR PLUS RIBAVIRIN CORAL-1 Study - (11/12/14)
![AASLD1.gif](../images/122214/122214-3/AASLD1.gif)
![AASLD2.gif](../images/122214/122214-3/AASLD2.gif)
![AASLD3.gif](../images/122214/122214-3/AASLD3.gif)
![AASLD4.gif](../images/122214/122214-3/AASLD4.gif)
![AASLD5.gif](../images/122214/122214-3/AASLD5.gif)
![AASLD6.gif](../images/122214/122214-3/AASLD6.gif)
![AASLD7.gif](../images/122214/122214-3/AASLD7.gif)
![AASLD8.gif](../images/122214/122214-3/AASLD8.gif)
![AASLD9.gif](../images/122214/122214-3/AASLD9.gif)
![AASLD10.gif](../images/122214/122214-3/AASLD10.gif)
![AASLD11.gif](../images/122214/122214-3/AASLD11.gif)
![AASLD12.gif](../images/122214/122214-3/AASLD12.gif)
![AASLD13.gif](../images/122214/122214-3/AASLD13.gif)
![AASLD14.gif](../images/122214/122214-3/AASLD14.gif)
![AASLD15.gif](../images/122214/122214-3/AASLD15.gif)
![AASLD16.gif](../images/122214/122214-3/AASLD16.gif)
![AASLD17.gif](../images/122214/122214-3/AASLD17.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|